Motus GI Holdings Inc (MOTS)
0.072
0.00 (0.00%)
USD |
OTCM |
May 01, 16:00
Motus GI Holdings Research and Development Expense (Quarterly): 0.561M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.561M |
| September 30, 2023 | 0.693M |
| June 30, 2023 | 0.759M |
| March 31, 2023 | 1.454M |
| December 31, 2022 | 1.35M |
| September 30, 2022 | 1.573M |
| June 30, 2022 | 1.413M |
| March 31, 2022 | 1.275M |
| December 31, 2021 | 1.301M |
| September 30, 2021 | 1.187M |
| June 30, 2021 | 1.508M |
| March 31, 2021 | 1.345M |
| December 31, 2020 | 1.196M |
| September 30, 2020 | 1.16M |
| June 30, 2020 | 1.264M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.935M |
| December 31, 2019 | 2.307M |
| September 30, 2019 | 2.173M |
| June 30, 2019 | 2.129M |
| March 31, 2019 | 2.404M |
| December 31, 2018 | 1.691M |
| September 30, 2018 | 1.77M |
| June 30, 2018 | 1.384M |
| March 31, 2018 | 1.203M |
| December 31, 2017 | 1.561M |
| September 30, 2017 | 0.965M |
| June 30, 2017 | 1.122M |
| March 31, 2017 | 0.614M |
| December 31, 2016 | 0.698M |
| September 30, 2016 | 0.498M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.561M
Minimum
Dec 2023
2.307M
Maximum
Dec 2019
1.399M
Average
1.345M
Median
Mar 2021
Research and Development Expense (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 6.08M |
| Retractable Technologies Inc | 0.1617M |
| Xtant Medical Holdings Inc | 0.492M |
| Asensus Surgical Inc | 8.614M |
| Catheter Precision Inc | -0.011M |